Drug Trial Radar · NCT01949129
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,800
Planned (sponsor's estimate)
Start
Apr 2013
Primary completion
Jun 1, 2030
Study completion Jun 1, 2030
Sponsor
- Lead sponsor
- St. Anna KinderkrebsforschungAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ALL SCTped Forum; European Society for Blood and Marrow Transplantation; ALL-BFM Study Group; Assistance Publique - Hôpitaux de Paris; Dutch Childhood Oncology Group; Swiss Pediatric Oncology Group; Australian & New Zealand Children's Haematology/Oncology Group
- First posted
- Sep 24, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 month, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen. The stratification of patients in first and following remissions according to the individual transplantation modalities rests upon an indication for allogeneic HSCT and the availability of a suitable donor within the individual transplantation groups.
Conditions
- Acute Lymphoblastic Leukaemia
Interventions
VP16Drug
60 mg/kg BW,1 day in TBI/VP16 conditioning; 40 mg/kg BW in Bu/VP16/Cy conditioning
TBIRadiation
2 x 2Gy/day , 3 days (total 12Gy)
ThiotepaDrug
2x5 mg/kg BW, 1 day
TreosulfanDrug
14g/m² BS, 3 days
FludarabineDrug
30 mg/m² BS, 5 days
BusulfanDrug
iV, dosage according therapeutic drug monitoring, 4 days
ATG ThymoglobulinDrug
MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
CyclophosphamideDrug
as part of conditioning 60 mg/kg BW 2 days or as GvHD Prophylaxis 50mg/kg BW/d 2 days with Mesna
GrafalonDrug
MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) Stratum 1a (randomisation TBI+ chemo-conditioning vs. chemo-conditioning only)Time frame: first: 18 months after inclusion of first patient, afterwards annually up to 10 years
- Event free survival (EFS) Stratum 2 (mismatched donor transplantation)Time frame: first: 18 months after inclusion of first patient, afterwards annually up to 10 years
- Overall Survival (OS), Stratum 1b: MSD/MD without randomisationTime frame: first: 18 months after inclusion of first patient, afterwards annually up to 10 years
Locations
119 sites in 31 countries. Site status is shown where the registry gives one.
Hospital de Pediatria "Juan P. Garrahan" Combate de Los Pozos N°1800 CABA
Buenos Aires, Argentina · Recruiting
Hospital Sor Maria Ludovica, Department Hematology Stem Cell Transplant Unit
La Plata, Argentina · Recruiting
Children's Cancer Centre The Royal Children's Hospital
Melbourne, Australia · Active not recruiting
Princess Margaret Hospital for Children
Perth, Australia · Active not recruiting
Sydney Children's Hospital
Randwick, Australia · Active not recruiting
Lady Cilento Children's Hospital
South Brisbane, Australia · Active not recruiting
The Children's Hospital at Westmead Oncology Unit
Sydney, Australia · Active not recruiting
Universitätsklinik für Kinder- und Jugendheilkunde, Abt. f. Hämato-Onkologie
Graz, Austria · Recruiting
Universitätsklinik für Kinder- und Jugendheilkunde
Innsbruck, Austria · Recruiting
St. Anna Children's Hospital, Vienna, Austria
Vienna, Austria · Recruiting
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Minsk, Belarus · Active not recruiting
Hôpital Universitaire des Enfants Reine Fabiola (HUDERF)
Brussels, Belgium · Recruiting
Cliniques Universitaires Saint-Luc (UCL) Hématologie et oncologie pédiatrique
Brussels, Belgium · Recruiting
University Hospital Gent Pediatrische hemato-oncologie
Ghent, Belgium · Recruiting
University Hospitals Leuven Kinderhemato-oncologie
Leuven, Belgium · Recruiting
Centre Hospitalier Universitaire de Liège Domaine Universitaire du Sart Tilman
Liège, Belgium · Recruiting
Alberta Children's Hospital Division of Pediatric Oncology
Calgary, Canada · Active not recruiting
Montreal Children's Hospital
Montral, Canada · Active not recruiting
CHU Sainte-Justine Hematology-Oncology Division
Montreal, Canada · Active not recruiting
Hospital for Sick Children University of Toronto Division of Haematology/Oncology
Toronto, Canada · Completed
BC Children's Hospital
Vancouver, Canada · Completed
CancerCare Manitoba/University of Manitoba
Winnipeg, Canada · Withdrawn
Hospital Dr Luis Calvo Mackenna
Santiago, Chile · Recruiting
Department of Pediatrics, UHC Zagreb
Zagreb, Croatia · Recruiting
Department of Pediatric Hematology and Oncology Teaching Hospital Motol, 2nd Medical School, Charles University
Prague, Czechia · Recruiting
Paediatric Stem Cell Transplant and Immune Deficiency, Dept. for children and adolescents 4072, Rigshospitalet
Copenhagen, Denmark · Recruiting
Division of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, Univ. of Helsinki
Helsinki, Finland · Completed
CHU Bordeaux
Bordeaux, France · Active not recruiting
CHU Clermont-Ferrand
Clermont-Ferrand, France · Active not recruiting
CHU Grenoble - Clinique Universitaire de Pédiatrie, Hôpital Couple Enfant
Grenoble, France · Active not recruiting
CHRU Lille, Service d'Hématologie Pédiatrique
Lille, France · Active not recruiting
IHOP / Lyon, Service Hématologie et d'Oncologie pédiatrique
Lyon, France · Active not recruiting
Hopital la Timone Adulte
Marseille, France · Active not recruiting
Hopital Arnaud de Villeneuve
Montpellier, France · Active not recruiting
CHU Nancy - Hopital d'Enfants
Nancy, France · Active not recruiting
CHU Nantes, Service d'onco hémato pédiatrie
Nantes, France · Active not recruiting
Hôpital Robert Debré
Paris, France · Active not recruiting
CHU de Rennes, Serive d'Onco-Pédiatrie
Rennes, France · Active not recruiting
CHU de Rouen, Hopital des Enfants, Service d' Immuno-Hématologie Oncologie Pédiatrique
Rouen, France · Active not recruiting
CHU Strasbourg, Service d'hématologie et d'oncologie pédiatrique
Strasbourg, France · Active not recruiting
Showing 40 of 119 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.